The Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination on Endothelial Function, Arterial Stiffness and Left Ventricular Deformation in Patients With Type 2 Diabetes With High Cardiovascular Risk
Latest Information Update: 08 Jun 2025
At a glance
- Drugs Empagliflozin (Primary) ; Liraglutide (Primary) ; Insulin; Metformin
- Indications Cardiovascular disorders; Type 2 diabetes mellitus
- Focus Pharmacodynamics
Most Recent Events
- 13 Sep 2024 Results assessing the effect of 12-month treatment with glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors and their combination on cardiac markers and mitochondrial function presented at the 60th Annual Meeting of the European Association for the Study of Diabetes
- 14 Mar 2024 Planned End Date changed from 30 Jun 2024 to 30 Jun 2027.
- 14 Mar 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2026.